<DOC>
	<DOCNO>NCT00808899</DOCNO>
	<brief_summary>A Phase II study temsirolimus combination standard chemotherapy ( irinotecan ; cyclophosphamide , doxorubicin etoposide ( CAE ) ; cisplatin etoposide ( HiPE ) topotecan ( TPT ) follow additional six course induction chemotherapy intensification autologous hematopoietic stem cell transplantation . The first five course induction chemotherapy also evaluate feasibility combine weekly temsirolimus standard chemotherapy combination . This follow 16 month oral maintenance therapy eight month 13-cis-retinoic acid eight month oral topotecan .</brief_summary>
	<brief_title>Neuroblastoma Protocol 2008 : Therapy Children With Advanced Stage High Risk Neuroblastoma</brief_title>
	<detailed_description>All child receive fix dos intravenous temsirolimus ( 50 mg/m2 weekly 6 time ) concomitantly two course fix dosage irinotecan ( 20 mg/m2 intravenously daily 5 time ,2 day , repeat daily 5 time .If initial dosage tolerable subsequent patient give reduced dosage temsirolimus ( 25 mg/m2 weekly 6 time ) 20 mg/m2 irinotecan.If dosage combination tolerable , irinotecan dosage decrease 15 mg/m2 .If dosage combination tolerable enrollment initial six week treatment terminated.The second course irinotecan begin day 22 response determine six week ( two course ) . Resection primary tumor attempt initial therapy , whenever possible . Following initial treatment child undergo alternate course induction chemotherapy cyclophosphamide , doxorubicin , etoposide , topotecan , cisplatin ( Block 2 ) . The first cohort 17 patient receive Block 2 temsirolimus ( 50mg/m2 ) three course , weekly 2 time . If tolerate subsequent patient receive Block 2 chemotherapy reduce dosage temsirolimus ( 25mg/m2 ) .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Patients &lt; 18 year old newly diagnose , advanced stage , highrisk neuroblastoma define one following : Children &lt; 1 yo International Neuroblastoma Staging System ( INSS ) stage 2a , 2b , 3 , 4 4S disease MYCN amplification ( &gt; 10 copy , great fourfold increase MYCN signal compare reference signal ) INSS 2a 2b disease MYCN amplification , regardless age additional biologic feature INSS stage 3 : 1 . MYCN amplification ( &gt; 10 copy , great fourfold increase MYCN signal compare reference signal , regardless age additional biologic feature 2 . Age &gt; 18 mo ( &gt; 547 day ) unfavorable pathology , regardless MYCN status INSS stage 4 : 1 . MYCN amplification , regardless age additional biologic feature 2 . Age &gt; 18 month ( &gt; 547 day ) regardless biologic feature 3 . Age 12 18 month ( 365 547 day ) follow three unfavorable biologic feature ( MYCN amplification , unfavorable pathology and/or DNA index =1 ) biologic feature indeterminant/unknown Children le equal 365 day initially diagnose : INSS stage 1 , 2 , 4S progress stage 4 without interval chemotherapy . Histologic proof neuroblastoma positive bone marrow tumor cell increase urine catecholamine . Adequate renal hepatic function ( serum creatinine &lt; 3 x upper limit normal age , ( AST ) aspartate aminotransferase &lt; 3 x upper limit normal ) . No prior therapy , unless emergency situation require local tumor treatment ( discuss PI ) Written , inform consent accord institutional guideline Any evidence , judge investigator , severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) . Pregnant breast feeding ( woman childbearing potential ) . Children INSS 4 disease , age &lt; 12 month 3 favorable biologic feature ( nonamplified MYCN , favorable pathology DNA index &gt; 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Neuroblastoma</keyword>
</DOC>